Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase 2 clinical trial for patients with adrenocortical carcinoma (ACC).
This rare and aggressive cancer, which affects the adrenal glands, has limited treatment options and an urgent need for new therapies.
CY-101, developed by Cytovation, is a synthetic peptide with a dual function. It selectively targets and destroys cancer cells, triggering a systemic immune response, while simultaneously inhibiting the Wnt/β-catenin signalling pathway,…
London, January 23, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for NeoPhore Limited and is pleased to announce the placement of Michael Shih as Chief Executive Officer (CEO) and Board of Director.NeoPhore, a small molecule neoantigen immuno-oncology company, is developing a pipeline of highly validated, first-in-class small molecule drugs targeting proteins across the DNA mismatch repair (MMR) pathway to improve the efficacy and durability of revolutionary…
https://www.globenewswire.com/news-release/2025/01/22/3013431/0/en/Cond…
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline
• Award winning Agility Life Sciences brings a proven track record in drug formulation for a number of pharmaceutical and biotechnology clients.
NAPLES, FL and CAMBRIDGE, UK, January 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced that it has entered into a strategic services agreement with formulation development CDMO Agility Life…
Cambridge, UK, 20 January 2025: Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced it has been listed in The Sunday Times 100 Tech, Britain's fastest-growing private technology companies. The inaugural feature, published 19th January, highlights the UK’s fastest-growing private companies developing or selling unique, proprietary technologies, and is backed by Singer Capital Markets, HSBC Innovation Banking and BDO.
Metrion provides preclinical drug discovery services to a growing network…
• £500K grant to advance discovery and development of effective precision antibiotics targeting antimicrobial-resistant lung infections in people with cystic fibrosis
• Programme delivered by CF AMR Syndicate offers cross-sector collaboration and support to address urgent unmet need
Glasgow, UK, 21 January 2025: Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has been awarded a share of the £3 million Collaborative Discovery Programme (CDP) launched by the Cystic Fibrosis Antimicrobial…
Pioneer Group, the life science infrastructure and venture building specialist, has joined forces with Innovate UK, The Medical Research Council (MRC) and AstraZeneca, to deliver the AI in Health Accelerator 2024/2025 Programme.
The Accelerator is designed to help entrepreneurs confidently market their AI-driven healthcare solutions and accelerate novel technology development time to market. The partners will collaborate across all elements of the Accelerator Programme, including its design and operation.
Ayokunmi Ajetunmobi, Head of Ventures at Pioneer, explains the rationale behind the…
Starting something new is hard – particularly within the fast-moving life science sector. Step forward Accelerate@Babraham, the Babraham Research Campus’ bio-incubator, founded out of a desire to support and nurture early-stage ventures; bringing to bear an unrivalled network of experts, mentors and investors and data-driven, comprehensive business analysis and support to equip these young enterprises with the skills, confidence and network connections to enable success.
Now in our seventh year, Accelerate@Babraham companies have raised £72.5m, have a current portfolio value estimated at over…
A state-of-the-art food and drink incubator that will house pioneering future food and beverage businesses is set to open at Colworth Science Park in Bedford in the heart of the UK’s ‘Golden Triangle.’
‘Gastronomica’ is the brainchild of Pioneer Group, which specialises in life science infrastructure and venture-building. The incubator is being created through a cooperation between Pioneer and Unilever. Colworth Science Park is home to one of Unilever’s Global R&D Innovation Centres, as well as other businesses pioneering future food and drink developments including DSM-Firmenich, Symrise…
Medicines Discovery Catapult (MDC), a national Life Sciences service dedicated to driving productivity and impact in drug R&D, has strengthened its Executive team with the appointment of a Chief Commercial Officer and its first Managing Director.
Dr Francesca Sadler has joined MDC as Chief Commercial Officer, bringing over 20 years’ experience in commercialising high-quality scientific services to both UK and international communities.
Responsible for MDC’s Communications, Commercial, and Business Development teams, Francesca will support the business in building on its external…
EZ-Spread™ Plating Beads from AMSBIO allow you to spread bacterial and yeast cells across the surface of an agar plate in just seconds.
Eliminating the traditional need for glass rods and potentially hazardous ethanol flaming - EZ-Spread plating beads provide a safer and more convenient method for spreading bacterial and yeast cells on agar plates.
Manufactured using precision molds, resulting in uniform shape and diameter, EZ-Spread plating beads ensure more even spreading of cells leading to increased colony formation compared to conventional methods.
Available in dispenser bottles suitable…